Britta Will, Ph.D., named director of Gottesman Institute for Stem Cell Research and Regenerative Medicine at Albert Einstein College of Medicine
Business Announcement
Updates every hour. Last Updated: 10-Jun-2025 23:09 ET (11-Jun-2025 03:09 GMT/UTC)
Albert Einstein College of Medicine has appointed Britta Will, Ph.D., associate professor of oncology, of medicine and of cell biology, and the Diane and Arthur B. Belfer Scholar in Cancer Research, as the permanent director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine.
People who experience depression following a stroke may face a higher risk of poor health and even death for up to a decade afterward, new research finds.
A large Mendelian randomization study, published in eGastroenterology by Liu et al., identified multisite chronic pain as a key causal factor for irritable bowel syndrome (IBS), along with links to depression, neuroticism, and gastro-esophageal reflux disease. The findings highlight chronic pain and mental well-being as priority targets for IBS prevention and call for integrated strategies addressing both gastrointestinal and psychiatric health.
A study published today in the Journal of Cancer Survivorship found that cancer survivors receiving high-cost immunotherapy treatments were more likely to face financial hardship, leading to increased instances of being unable to afford care and taking fewer medications due to cost.
The research, focusing on Medicare-enrolled patients, investigated the financial challenges faced by cancer survivors, particularly those receiving expensive immunotherapies.
“Although it’s well-known that many cancer patients experience financial hardship due to healthcare costs, there’s not much research available that specifically assesses the financial strain linked to immunotherapy treatments, particularly among Medicare enrollees,” said the study’s senior author Cathy Bradley, PhD, Dean of the Colorado School of Public Health on the University of Colorado Anschutz Medical Campus. “As more therapies are developed and the cost of drugs continues to increase, it’s important to determine if patients, even those who are insured, can afford out-of-pocket costs or if these costs are becoming a barrier to access life-saving treatment.”